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Abstract
A response to Ege E, Dereli Y, Kurban S, Sarigul A: Atorvastatin pretreatment diminishes the levels of
myocardial ischemia markers early after CABG operation: an observational study. J Cardiothorac Surg 2010,
5:60.
Correspondence
We read with great interest the manuscript by Ege et al
[1] concerning how Atorvastatin pretreatment before
CABG diminishes the levels of myocardial ischemia
biomarkers.
Our study [2] was the first to report that preoperative
treatment with statins reduces biochemical parameters
of systemic inflammatory response and myocardial
ischemia markers in cardiac surgery with cardiopulmon-
ary bypass (CPB), regardless of being CABG or valvular
surgery.
M a n n a c i oe ta l[ 3 ]p u b l i s h e dt h ef i r s tr a n d o m i z e d
study showing that pretreatment with rosuvastatin
decreases the incidence of myocardial damage in
patients undergoing coronary surgery with CPB. In our
study Creatine phosphokinase (CPK), CPK-MB and tro-
ponin I was assessed at 1, 6, and 24 h after surgery in
138 patients who underwent cardiac surgery with CPB.
The levels observed in the statin treatment group were
always lower than those in the group that did not
receive treatment, this difference only being significant
in the measurement of CPK-MB at 24 h (19.7 ± 23 ng/ml
vs 33.1 ± 32.6 ng/ml, p = 0.02) and in the sample col-
lected of Troponin I at the end of the intervention (2.25
± 2.2 ng/ml vs 3.32 ± 3.1 ng/ml, p = 0.03) and at 24 h
(4.15 ± 3.54 ng/ml vs 6.64 ± 8.08 ng/ml, p = 0.04). These
findings coincide with the single measurement at 24 h
after surgery in the manuscript by Ege et al (for CK-MB
levels, 12.9 ± 4.3 versus 18.7 ± 7.4 ng/ml, p = 0.004;
for troponin I levels, 1.7 ± 0.3 versus 2.7 ± 0.7 ng/ml,
p < 0.001). The higher levels of CPK-MB and Troponin I
we found in our study could be explained by the mixed
valvular and coronary population, beeing similar with the
findings of Landoni G et al [4]. This study demonstrated
that each type of cardiac operation has a peculiar amount
of myocardial necrosis biomarkers; the highest release of
these cardiac biomarkers was associated with mitral valve
replacement [4].
Ege et al [1] reports that the study group received mini-
mum 20 mg/kg/day atorvastatin (Ator, Sanovel, Istanbul,
Turkey) for at least 15 days before surgery, and we
assume that they wish to mean 20 mg/day atorvastatin.
T h et y p eo fs t a t i nw eu s e dm o s tw a sa t o r v a s t a t i n
(63.9%) and the most common dose was 20 mg per day
at least 3 weeks before surgery [2]. Mannacio et al [3]
used 20 mg/day of rosuvastatin one week before surgery.
Therefore, it seems possible to achieve the same results,
even with low doses of statins and in less time before
surgery.
Recent studies performed in patients undergoing car-
diac surgery found that statins reduced the mid-term
mortality and the number of postoperative complica-
tions and clinical events[5]; the common feature of
these publications were the large amount of patients
necessary to achive clinical results. Ege et al [1] found a
shorter duration of ICU stay among patients treated
with atorvastatin in an study with only forty cases. In
our prospective cohort of 138 patients [2], the different
groups analyzed did not show differences with regard to
any of the postoperative variables. Therefore, this results
should be interpreted cautiously, until future studies
with larger sample sizes confirm these findings.
In CABG without myocardial infarction, the amount
of cardiac biomarker released seemed to be associated
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events [6]. According to this facts an absolute reduction
of marker release, as observed in these studies [1-3],
could be translated into a reduction of early and late
adverse events. The anti-inflammatory action of statins,
as we demonstrated [2], its pleiotropic effects and the
capacity of reduction of myocardial biomarkers, are the
reasons of the potencial beneficial effects of statins in
cardiac surgery interventions.
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